Upper GI Tract
From the Journals
PPI use in type 2 diabetes links with cardiovascular events
Prospective data from almost 20,000 people with type 2 diabetes show that proton pump inhibitor use is linked with significantly more...
From the Journals
Expert panel forms strategy for eosinophilic esophagitis monitoring
The panel had the most trouble reaching a consensus on how often to follow up on patients whose disease is in remission or is stable. They settled...
From the Journals
High rates of inappropriate PPI use in hospitalized patients
“PPI overprescription is a common problem worldwide, with the United States being no exception.”
From the Journals
Higher BMI may dampen steroid response in eosinophilic esophagitis
“While these findings may not yet affect current management, it highlights the need for more prospective research to see if dosing adjustment,...
From the AGA Journals
Vonoprazan promising for erosive esophagitis
“PCABs are a promising new option.” They have a “more potent acid inhibitory effect” and have shown “superior healing of erosive esophagitis.”
Conference Coverage
Dupilumab improves eosinophilic esophagitis up to 24 weeks
The drug received FDA approval for EoE treatment earlier in 2022.
Conference Coverage
Risk factors ID’d for acute pancreatitis from weight-loss drugs
“With obesity being such a global issue, there are many patients on these GLP-1 agonists.”
From the Journals
Time to ditch clarithromycin for H. pylori?
“This study shows that multiple parts of the United States and Europe have high resistance rates.”
From the AGA Journals
Experts refine nomenclature for eosinophilic GI diseases
The consensus paper defines subtypes for clinical and research purposes.
From the AGA Journals
Experts refine nomenclature for eosinophilic GI disorders
The consensus paper defines subtypes for clinical and research purposes.